According to our analysis, MS treatment is a complex process involving multiple systemic pathways, including immunity, infection, and signal transduction, etc. We should focus on candidate drugs that target both the “PI3K-Akt signaling pathway” and the “Chemokine signaling pathway” (e.g., Nemiralisib and Umbralisib) and TKI (e.g., Fostamatinib). The gene discussed is AKT1; the disease is infection.